NeuraSignal’s cover photo
NeuraSignal

NeuraSignal

Medical Device

Los Angeles, California 9,794 followers

About us

In 2023 NeuraSignal, Inc. acquired the business of NovaSignal, the original developer of NovaGuide. NeuraSignal is a medical technology company with a mission to save lives by unlocking the power of cerebral blood flow data. The company’s FDA-cleared NovaGuide Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real time. Using cloud computing and data analytics, NeuraSignal supports physicians in their clinical decision making in several neurological conditions including stroke, traumatic brain injury, and dementia. To learn more, visit www.NeuraSignal.com.

Industry
Medical Device
Company size
11-50 employees
Headquarters
Los Angeles, California
Type
Privately Held
Specialties
Ultrasound, Data Science, Stroke, AI, and Cloud

Locations

Employees at NeuraSignal

Updates

  • Fresh off the Presses! NeuraSignal is revolutionizing stroke care with real-time, intelligent ultrasound! 🧠⚡ We’re thrilled to see the NG2 Intelligent Ultrasound featured in this latest AP News release, highlighting its impact on stroke detection, vasospasm monitoring, and patient outcomes. With advanced automation and AI-driven insights, we’re making Transcranial Doppler (TCD) ultrasound more accessible, reliable, and powerful than ever before. 🔗 Read the full story: https://bit.ly/3FAFljA Join us in shaping the future of neurovascular care. #NeuraSignal #NG2 #StrokeCare

  • For the first time ever, NeuraSignal is exhibiting at the American College of Cardiology (ACC) Annual Meeting in Chicago, March 29-31! 📍 Visit us at Booth #8076 to see how the NG2 Intelligent Ultrasound achieves 3X the detection rate compared to TTE for PFO in proven real-world clinical settings. Don't miss this opportunity to experience cutting-edge innovation and chat with our experts! See you there! 👏 #ACC24 #NeuraSignal

    • No alternative text description for this image
  • 💙 Celebrating Women in Medicine for National Women's Month! 💙 This month, we honor the incredible women who are shaping the future of medicine, from groundbreaking research to life-saving patient care. At NeuraSignal, we are proud to support and work alongside the brilliant women advancing neurology, cardiology, and stroke care every day. Your dedication, innovation, and leadership inspire us all! Thank you for your impact on healthcare and the lives you change. Tag a woman in medicine who inspires you! 👩⚕️💡 #WomenInMedicine #NationalWomensMonth #NeuraSignal #HealthcareInnovation

    • No alternative text description for this image
  • Take it from Willy – See More, Treat More! 🐳 NeuraSignal’s NG2 Intelligent Ultrasound detects right-to-left shunts (RLS) 3X better than standard TTE, meaning more treatable cases are found, and fewer go undetected. 💡 27% detection vs. just 10% with traditional methods 🔍 More accuracy. More interventions. Better outcomes. When it comes to stroke prevention and PFO detection, seeing the whole picture makes all the difference. #NeuraSignal #NG2 #PFO

    • No alternative text description for this image
  • Peer-Reviewed & Published: NG2 Redefines RLS & PFO Detection! 🚀 Exciting news! We’re thrilled to announce that a groundbreaking study by Dr. Thomas Devlin and his research team has been accepted and published in Frontiers of Neurology. This study highlights how robotic transcranial Doppler (raTCD) significantly outperforms transthoracic echocardiography (TTE) in detecting right-to-left shunts (RLS) and patent foramen ovale (PFO)—critical factors in cryptogenic stroke. 🔬 Key Findings: ✅ 60.1% RLS detection with raTCD vs. 37.2% with TTE (p < 0.001) ✅ 42.6% detection of large shunts vs. 23.0% with TTE (p < 0.001) ✅ 92% sensitivity & 87.5% specificity—outperforming TTE (78.57% & 71.43%) ✅ 100% correct identification of large shunts in PFO closure patients, while TTE missed or underestimated PFO size in 44% of cases 💡 Why This Matters: These results reinforce NG2 as a superior, non-invasive screening tool for PFO detection and stroke prevention. By accurately identifying large shunts, NG2 helps guide treatment decisions and improve patient outcomes—ensuring fewer missed diagnoses and better stroke prevention strategies. Read the full publication here: https://bit.ly/41rkciT

  • ❤️ February is American Heart Month! ❤️ At NeuraSignal, we’re dedicated to advancing stroke and cardiac care through smarter, more precise ultrasound technology. This month, we join the movement to raise awareness about heart health, early detection, and innovation in cardiovascular care. Did you know? Undetected right-to-left shunts (RLS) can increase stroke risk—but with NG2 Intelligent Ultrasound, clinicians can detect 3X more shunts compared to standard TTE imaging. More detection means more opportunities for intervention and better patient outcomes. Let’s work together to protect hearts and prevent strokes. 💡💙 #AmericanHeartMonth

    • No alternative text description for this image
  • 📸 Teamwork in Action at NeuraSignal! At NeuraSignal, we believe that the best innovations happen when great minds come together. Our latest team photo is more than just a snapshot—it’s a reflection of the collaboration, creativity, and shared passion that drive us every day. From brainstorming breakthroughs to solving complex challenges, our team is the heartbeat of everything we do. We celebrate each win together, support each other through the hurdles, and push the boundaries of what’s possible. Here’s to the people who make NeuraSignal more than just a company—our incredible team!

    • No alternative text description for this image
  • 🚨 BREAKING NEWS! 🚨 Just published! Our groundbreaking research on robot-assisted transcranial Doppler (raTCD) for right-to-left shunt (RLS) detection has now been published in Frontiers in Neurology! 🎉 This study confirms that raTCD detects 1.7X more cases of RLS/PFO compared to TTE, reinforcing its role in stroke prevention and cardiac risk assessment. Read how NG2 is revolutionizing bubble studies and why cardiologists & stroke specialists are turning to automated TCD for faster, more accurate diagnostics. Read full blog here: https://bit.ly/3XbjAwR

  • Last week, we had a packed house at the Wake Forest TCD Workshop, where clinicians got hands-on with NG2 Intelligent Ultrasound and explored the power of robot-assisted TCD (raTCD) for cerebral blood flow monitoring. 👥 From live demonstrations to insightful discussions on stroke diagnostics and PFO detection, it was incredible to see so much enthusiasm for advancing neurovascular care! A huge thank you to everyone who joined us! 🙌

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • NeuraSignal would like to congratulate Dr. Thomas Devlin on his impactful presentation at ISC 2025, showcasing the "Multicenter Validation Study of Robot-Assisted Transcranial Doppler (raTCD) for Enhanced Right-to-Left Shunt Detection". This groundbreaking research reinforces the power of the NG2 in detecting PFO and RLS more effectively than traditional modalities, further advancing stroke diagnostics and patient care. Pushing the boundaries of neurovascular innovation—one study at a time! 👏 Join us in celebrating Dr. Devlin and the entire research team for their dedication to improving stroke detection and treatment! #ISC2025 #NeuraSignal #NG2 #StrokeDetection #TCD #PFO

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image

Similar pages

Browse jobs